CANDEL THERAPEUTICS, INC. (CADL) Current Ratio
- Current ratio · latest quarter: Value 16.09×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 16.09× | Current assets / current liabilities. $204.16M ÷ $12.69M ≈ 16.09× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 204.16M USD | Assets, Current |
| Current obligations | 12.69M USD | Liabilities, Current |
| Cash and equivalents | 201.56M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 5.15M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $204.16M | $12.69M | $201.56M | (m) | (m) | (m) | $5.15M | (m) | 16.09× |
| 2026-03-31 | $197.75M | $7.05M | $194.83M | (m) | (m) | (m) | $3.04M | (m) | 28.05× |
| 2025-12-31 | $121.39M | $9.00M | $119.73M | (m) | (m) | (m) | $1.13M | (m) | 13.49× |
| 2025-09-30 | $90.13M | $10.93M | $86.96M | (m) | (m) | (m) | $1.12M | $4.22M | 8.25× |
| 2025-06-30 | $103.61M | $14.71M | $100.69M | (m) | (m) | (m) | $1.95M | $6.70M | 7.04× |
| 2025-03-31 | $93.15M | $20.07M | $92.17M | (m) | (m) | (m) | $760.00K | $9.17M | 4.64× |
| 2024-12-31 | $103.80M | $37.53M | $102.65M | (m) | (m) | (m) | $237.00K | $9.89M | 2.77× |
| 2024-09-30 | $18.09M | $15.27M | $16.56M | (m) | (m) | (m) | $296.00K | $9.85M | 1.18× |
| 2024-06-30 | $22.73M | $14.00M | $21.45M | (m) | (m) | (m) | $433.00K | $9.81M | 1.62× |
| 2024-03-31 | $27.14M | $13.54M | $25.71M | (m) | (m) | (m) | $472.00K | $9.77M | 2.00× |
| 2023-12-31 | $36.80M | $14.18M | $35.41M | (m) | (m) | (m) | $422.00K | $8.89M | 2.59× |
| 2023-09-30 | $45.10M | $10.33M | $42.98M | (m) | (m) | (m) | $250.00K | $6.10M | 4.37× |
| 2023-06-30 | $53.36M | $8.16M | $51.89M | (m) | (m) | (m) | $480.00K | $3.65M | 6.54× |
| 2023-03-31 | $61.88M | $5.24M | $59.26M | (m) | (m) | (m) | $592.00K | $1.25M | 11.82× |
| 2022-12-31 | $71.94M | $5.62M | $70.06M | (m) | (m) | (m) | $380.00K | (m) | 12.81× |
| 2022-09-30 | $79.07M | $5.90M | $77.18M | (m) | (m) | (m) | $970.00K | (m) | 13.41× |
| 2022-06-30 | $87.33M | $5.88M | $86.78M | (m) | (m) | (m) | $1.58M | (m) | 14.86× |
| 2022-03-31 | $95.65M | $5.47M | $94.32M | (m) | (m) | (m) | $1.39M | (m) | 17.48× |
| 2021-12-31 | $84.94M | $5.36M | $82.64M | (m) | (m) | (m) | $1.59M | (m) | 15.84× |
| 2021-09-30 | $90.95M | $4.40M | $88.39M | (m) | (m) | (m) | $925.00K | (m) | 20.68× |
| 2021-06-30 | $24.43M | $4.49M | $24.32M | (m) | (m) | (m) | $759.00K | (m) | 5.44× |
| 2020-12-31 | $35.15M | $4.71M | $35.05M | (m) | (m) | (m) | $921.00K | (m) | 7.46× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |